Kobayashi Pharmaceutical Co., Ltd.
4967
Classifica tra le azioni
#4483
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries,... Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Prezzo delle azioni
$45.65
Capitalizzazione di mercato
$3.39B
Variazione (1 giorno)
-0.40%
Variazione (1 anno)
30.30%
Paese
JP
Scambia Kobayashi Pharmaceutical Co., Ltd. (4967)
Categoria
Consumer Defensive
Rapporto P/B per Kobayashi Pharmaceutical Co., Ltd. (4967)
Rapporto P/B al October 2026 TTM: 2.53
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kobayashi Pharmaceutical Co., Ltd., il rapporto P/B attuale (TTM) è 2.53. Alla fine del 2024, era pari a 2.17.
Storico del rapporto P/B per Kobayashi Pharmaceutical Co., Ltd. da 2005 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 2.53 | 32.71% |
| 2025 | 1.91 | -11.85% |
| 2024 | 2.17 | -13.71% |
| 2023 | 2.51 | -28.55% |
| 2022 | 3.52 | -2.54% |
| 2021 | 3.61 | -33.11% |
| 2020 | 5.40 | 28.22% |
| 2019 | 4.21 | 18.56% |
| 2018 | 3.55 | -5.31% |
| 2017 | 3.75 | 34.44% |
| 2016 | 2.79 | 11.09% |
| 2015 | 2.51 | 30.83% |
| 2014 | 1.92 | 22.50% |
| 2013 | 1.57 | -5.85% |
| 2012 | 1.66 | -3.73% |
| 2011 | 1.73 | -7.26% |
| 2010 | 1.86 | 6.76% |
| 2009 | 1.75 | -15.18% |
| 2008 | 2.06 | -24.00% |
| 2007 | 2.71 | 4.07% |
| 2006 | 2.60 | 28.50% |
| 2005 | 2.03 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.9837 | 175.51% |
US
|
|
| 6.3772 | 151.59% |
FR
|
|
| 315.2455 | 12,336.70% |
US
|
|
| 8.7627 | 245.70% |
IN
|
|
| 9.8894 | 290.15% |
US
|
